Although there have been some reports claiming that the reduced glucose tolerance would be involved as a risk factor to IHD, we have earlier reported that the reduce of glucose tolerance is not always an important factor to IHD, but rather the abnormal pattern of FFA decrease during glucose loading would play a role as the accerelating factor to the occurrence of IHD which can not be neglected. In the present report, the effects of PGE
1 upon the carbohydratelipid metabolism to 50g-OGGT were investingated in relation to the pathophysiological mechanism of the Type B-FFA pattern as seen in the patient of IHD. In 20 cases of the patients with IHD showing the Type B-FFA pattern, PGE
1 (0.6μg/min.) with physiological saline 250m
l was continuously infused into the right cubital vein for 180min. simultaneously with the start of 50g-OGTT, FFA, IRI and sugar in the venous blood sample were measured before, 30, 60, 90, 120 and 180min. after glucose loading. These biochemical variations were comparatively evaluated with the variations observed when PGE
1 was not administered. As a result, the following were found out:
1) The effects of PGE
1 upon the Type B-pattern of FFA may be elucidated by that the Type B was changed into Type A following administration of PGE
1. Specifically, the FFA values without administration of PGE
1 were significantly lowered respectively to 0.009±0.05 and 0.09±±0.04 at 120 and 180 minutes after the loading in comparison of 0.45± 0.31 prior to the loading. On the other hand, the FFA value with PGE
1 administration amounted to 0.29±0.17 at 180 minutes after loading against 0.43±0.22 which was before loading, showing no signicant difference and the recovery of the oncedropped FFA level in blood into the prior level in 180 minutes after loading. The FFA values at 90, 120, and 180 minutes with administration of PGE
1 were significantly higher that those without administration of PGE
1.
2) In terms of there lationship between FFA
f and FFA
90′ or FFA
180′ no significant correlation was found between the two when PGE
1 was not adimistered, and the drop in the blood FFA during GTT varied with independence on the values prior to the loading, whereas, with administration of PGE
1 significant positive correlation was not between the two, with a correlation coefficient of r=0.865 and 0.885 with P<0.001. After loading, the blood levels of FFA varied with dependence on the values prior to the loading.
3) In the terms of the effects of PGE
1 upon the IRI level in the circulating blood the insulin secretion during the GTT was inhibited when PGE
1 was administered, against the values without administration of PGE
1. Specifically, the IRI
30′ and IRI
60′ with administration of PGE
1 were respectively 24±14μU/d
l and 35±20μU/d
l, whereas the counterparts without administration of PGE
1 were 47±30μU/d
l and 56±36μU/d
l indicating significant decrease and also a trend that the IRI
90′ IRI
120′ and IRI
180′ were lowered by the administration of PGE
1.
4) No effect was observed upon the glucose loading by the administration of PGE
1 and there was no significant difference between the blood sugar levels during the loading with administration of PGE
1 and the blood sugar levels without administration of PGE
1.
Conclusion: On the basis on the above results, a mechanism was assumed to exist that the decsease of FFA in blood in the patients with IHD would be abnormally delayed due to the excessive secretion of insulin against GTT, and it was also suggested that the overscretion of insulin
View full abstract